Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hydrallazine in hypertension: is there a safe dose?

× No keyword cloud information.

3 in total

Review 1. Late toxicity to hydralazine resembling systemic lupus erythematosus or rheumatoid arthritis.

Authors: H M Perry
Journal: Am J Med Date: 1973-01 Impact factor: 4.965

2. Simplified method for determining acetylator phenotype.

Authors: H Schröder
Journal: Br Med J Date: 1972-08-26

3. Relationship of acetyl transferase activity to antinuclear antibodies and toxic symptoms in hypertensive patients treated with hydralazine.

Authors: H M Perry; E M Tan; S Carmody; A Sakamoto
Journal: J Lab Clin Med Date: 1970-07

3 in total

13 in total

1. Acrylamine-induced autoimmune phenomena.

Authors: Bruce Rothschild
Journal: Clin Rheumatol Date: 2010-06-11 Impact factor: 2.980

2. The third drug in hypertension.

Authors: A Breckenridge
Journal: Br Med J (Clin Res Ed) Date: 1984-10-06

3. Hydralazine-induced necrotising vasculitis.

Authors: A Peacock; D Weatherall
Journal: Br Med J (Clin Res Ed) Date: 1981-04-04

4. Transient monoclonal gammopathy in hydralazine-induced lupus erythematosus.

Authors: S Freestone; L E Ramsay
Journal: Br Med J (Clin Res Ed) Date: 1982-11-27

5. Endralazine in patients with severe hypertension and renal insufficiency.

Authors: E R Higgs; P R Harrison; R A Banks; J C Kingswood; J C Mackenzie
Journal: Postgrad Med J Date: 1982-12 Impact factor: 2.401

6. The lupus syndrome induced by hydralazine: a common complication with low dose treatment.

Authors: H A Cameron; L E Ramsay
Journal: Br Med J (Clin Res Ed) Date: 1984-08-18

7. The addition of prazosin to standard triple therapy in the treatment of severe hypertension.

Authors: A M Heagerty; G I Russell; R F Bing; H Thurston; J D Swales
Journal: Br J Clin Pharmacol Date: 1982-04 Impact factor: 4.335

8. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?

Authors: L E Ramsay; J H Silas; J D Ollerenshaw; G T Tucker; F C Phillips; S Freestone
Journal: Eur J Clin Pharmacol Date: 1984 Impact factor: 2.953

9. "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors: D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal: Br Med J (Clin Res Ed) Date: 1984-01-14

10. Endralazine, a new peripheral vasodilator. Evaluation of safety and efficacy over a 3 year period.

Authors: W A Bogers; L Meems
Journal: Eur J Clin Pharmacol Date: 1983 Impact factor: 2.953